Read our latest updates & insights

Biora Therapeutics announced preliminary results from preclinical testing of PGN-0B1, reporting an average bioavailability greater than 50% for a variant of adalimumab. Biora’s systemic therapeutics platform uses an ingestible capsule for needle-free, oral delivery of bioth...

Organon published its results for Q4 and full year ended 31 December 2022, reporting a second consecutive year of double-digit revenue growth in biosimilars. Organon reported that this growth was primarily drive by double-digit growth from Renflexis® (biosimilar to Johnson ...

Coherus and Junshi Biosciences published the results of Ph III trials of toripalimab in JUPITER-02 (NCT03581786), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as the first-line tre...

Henlius announced that the FDA has accepted its BLA for HLX02 (trastuzumab, biosimilar to Roche’s Herceptin®). According to the release, this is the first Chinese biosimilar to be approved in both China and the EU and may be the first to be approved in the US.

JSR Life Sciences’ Similis Bio announced plans to enter into a partnership with Novel351K to co-develop three undisclosed biosimilar programs.  Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP produ...

Significant biosimilar activities this week include:

09 Feb 23 | EU | EMA accepts MAA for Alvotech’s AVT04 (ustekinumab biosimilar)

Alvotech and STADA announced that EMA has accepted the MAA for Alvotech’s AVT04 biosimilar to Janssen’s Stelara™.  The companies...

A new Fresenius Kabi study published in the Expert Review of Clinical Immunity has confirmed pharmacokinetic bioequivalence between a tocilizumab biosimilar and a US-licensed tocilizumab (Actemra®). The authors also found that the safety profiles were similar. Tocilizumab i...

Biocon announced that the FDA has issued a Complete Response Letter for Viatris (Mylan)’s BLA regarding the bevacizumab jointly developed with Biocon Biologics (biosimilar to Genentech’s Avastin®).  Biocon Biologics said in the announcement that is has submitted a comprehen...

Celltrion and Samsung Bioepis each filed motions seeking joinder of their respective IPR challenges to Regeneron’s 10,888,601 and 10,130,681 patents for Eylea® (aflibercept) with Mylan’s, which was instituted in January 2023.

PTAB also instituted Mylan’s IPR against ...

Samsung Bioepis filed a petition for inter partes review of Regeneron’s US 10,888,601, relating to Eylea® (aflibercept).  In August 2022, Regeneron sued Viatris (Mylan) for infringement of 24 patents relating to Eylea, including the‘601 patent.